BioTuesdays

Author - Leonard Zehr

novadaq
Developments

Novadaq posts 52% jump in Q1 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported first quarter revenue of $17.7-million, up 52%, from $11.7-million a year ago. Total direct sales in the quarter rose by $6.1-million, or 71%, and total...

April 27, 2016
Trovagene Logo
Markets

Leerink downgrades Trovagene to market perform

Leerink Partners has downgraded Trovagene (NASDAQ:TROV) to “market perform” from “outperform” and lowered its price target to $4.50 from $8, following the recent removal/departure of key senior management. The stock...

April 26, 2016
Feature

In conversation with Paul Gunn

By Len Zehr As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by...

April 26, 2016
Celator Pharmaceuticals
Markets

Stifel starts Celator Pharma at buy

Stifel has initiated coverage of Celator Pharmaceuticals (NASDAQ:CPXX) with a “buy” rating and a 12-month target price of $23. The stock closed at $15.52 on Thursday. Analyst Stephen Willey writes that recently...

April 22, 2016
Windtree Therapeutics
Markets

HCW starts Windtree Therapeutics at buy

H.C. Wainwright has launched coverage of Windtree Therapeutics (NASDAQ:WINT) with a “buy” rating and $8 price target, ahead of study readouts on tap for the next 12 months. The stock closed at $3.03 on Thursday. “We...

April 22, 2016
Cerus
Markets

BTIG ups Cerus price target to $10

BTIG Research has raised its price target for Cerus (NASDAQ:CERS) to $10 from $8, saying the progress made by the company has “exceeded even our bullish expectations.” The stock closed at $6.65 on Thursday. Cerus is a...

April 22, 2016
BIOSIGHT
Developments

BioSight completes Phase 1/2a leukemia trial

Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months. The Phase 1/2a trial is an...

April 20, 2016